Company profile: Atriva Therapeutics
1.1 - Company Overview
Company description
- Provider of host-targeting antiviral therapies for respiratory viral infections. Its lead candidate, zapnometinib (ATR-002), is an orally available small molecule designed to inhibit viral replication and modulate immune response to treat severe RNA-virus infections. Completed a Phase I safety study; assessing efficacy and safety in a Phase II study in hospitalized severe COVID-19 and planning Phase II development for severe influenza.
Products and services
- Zapnometinib (ATR-002): An orally available small-molecule drug that inhibits viral replication and modulates immune responses to treat severe RNA-virus infections via a host-targeting mechanism
- Phase II study for COVID-19: A hospital-based evaluation of the efficacy and safety of zapnometinib in hospitalized patients with severe COVID-19
- Host-targeting antiviral therapies: A host-directed development program creating therapies that target host cell mechanisms to treat respiratory viral infections, making viral resistance less likely
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Atriva Therapeutics
Tetraphase Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutics for significant disease categories, including GIAPREZA to increase blood pressure in adults with septic or other distributive shock; XERAVA for complicated intra-abdominal infections in adults; XACDURO for hospital- and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter baumannii-calcoaceticus complex; and investigational zoliflodacin for uncomplicated gonorrhea.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tetraphase Pharmaceuticals company profile →
Rebiotix
HQ: United States
Website
- Description: Provider of microbiome-based therapeutics targeting GI diseases, including FDA-approved REBYOTA for prevention of recurrence of Clostridioides difficile infection in adults; RBX2660, a live biotherapeutic in development for recurrent C. difficile; RBX7455, a non-frozen capsule in feasibility studies; and a Stool Donor Program supporting development of microbiome-based therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rebiotix company profile →
MorphoChem
HQ: Germany
Website
- Description: Provider of innovative intravenous therapy for Clostridium difficile infection (CDI), based on novel antibacterial MCB3681, addressing an unmet medical need and aiming to make a difference for CDI patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MorphoChem company profile →
OraSure Technologies
HQ: United States
Website
- Description: Provider of oral fluid diagnostic and collection devices, offering rapid infectious disease tests (HIV, Hepatitis C, COVID-19, Ebola, influenza), oral fluid-based substance abuse testing, DNA Genotek DNA/RNA sample collection kits for genomics and microbiome research, and the Novosanis Colli-Pee device for first-void urine detection of urological cancers and sexually transmitted infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OraSure Technologies company profile →
Amicrobe
HQ: United States
Website
- Description: Provider of advanced biomaterials to prevent and treat infections, offering Amicidin-α Surgical gel for clean and clean-contaminated surgical procedures; Amicidin-β Solution for contaminated and infected tissues with tissue cleansing and microbicidal activity; Amicidin-α PFC for military prolonged field settings (up to 72 hours); and Amicidin-β/EF for emergency settings, including trauma and emergency cesarean delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amicrobe company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Atriva Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Atriva Therapeutics
2.2 - Growth funds investing in similar companies to Atriva Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Atriva Therapeutics
4.2 - Public trading comparable groups for Atriva Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →